R&D

Pipeline

New Drug Development Status

Last updated 2018-04-22

BIO
Research
Area
Project Indication Preclinical Clinical Licensing
Phase 1 Phase 2 Phase 3
BIO

Rolontis(eflapegrastim)

Every three weeks administration*Spectrum code: SPI-2012

  • Preclinical
  • Phase 1
  • Phase 2
  • Phase 3

Spectrum

Chemotherapy-
induced neutropenia

complete

complete

complete

ongoing

Spectrum

efpeglenatideLAPSExd4 Analog

Once weekly~monthly (GLP-1)*Sanofi code: SAR-439977

  • Preclinical
  • Phase 1
  • Phase 2
  • Phase 3

Sanofi

Diabetes & Obesity

complete

complete

complete

ongoing

Sanofi

efpegsomatropin(LAPShGH)

Once weekly administration

  • Preclinical
  • Phase 1
  • Phase 2
  • Phase 3

none

Growth hormone
deficiency

complete

complete

complete

uncompleted

none

HM12525A(LAPSGLP/GCG)

Once weekly administration*Janssen code: JNJ-64565111

  • Preclinical
  • Phase 1
  • Phase 2
  • Phase 3

Janssen

Diabetes & Obesity

complete

complete

ongoing

uncompleted

Janssen

HM12460A / HM12470(LAPSInsulin / LAPSInsulin Analog)

A long-acting insulin or insulin

Once weekly administration

  • Preclinical
  • Phase 1
  • Phase 2
  • Phase 3

none

Type 1 & 2 Diabetes

complete

complete

uncompleted

uncompleted

none

HM15211(LAPSTriple Agonist)

Once weekly administration (GLP/GIP/GCG)

  • Preclinical
  • Phase 1
  • Phase 2
  • Phase 3

none

Obesity/NASH

complete

ongoing

uncompleted

uncompleted

none

HM14220LAPSInsulin Combo

efpeglenatide +LAPSInsulin Analog

Once weekly administration

  • Preclinical
  • Phase 1
  • Phase 2
  • Phase 3

Sanofi

Type 2 Diabetes

complete

uncompleted

uncompleted

uncompleted

Sanofi

HM15136(LAPSGlucagon Analog)

Once weekly administration (Glucagon)

  • Preclinical
  • Phase 1
  • Phase 2
  • Phase 3

none

Cogenitial
hyperinsulinism

complete

uncompleted

uncompleted

uncompleted

none

HM15450(LAPSASB)

Once monthly administration (LSD treatment)

  • Preclinical
  • Phase 1
  • Phase 2
  • Phase 3

none

Mucopolysaccharidosis

ongoing

uncompleted

uncompleted

uncompleted

none

HM15912(LAPSGLP-2 Analog)

Once weekly administration (GLP-2)

  • Preclinical
  • Phase 1
  • Phase 2
  • Phase 3

none

Short bowel syndrome

complete

uncompleted

uncompleted

uncompleted

none

HM21001(GBM Stem Cell Therapy)

Glioblastoma (GBM) stem cell therapy

  • Preclinical
  • Phase 1
  • Phase 2
  • Phase 3

없음

Glioblastoma

ongoing

uncompleted

uncompleted

uncompleted

Ajou University

NCE
Research
area
Project Indication Preclinical Clinical Licensing
Phase 1 Phase 2 Phase 3
NCE

Oraxol(paclitaxel + HM30181A)

Oral paclitaxel

HM30181A: Oral absorption enhancer

  • Preclinical
  • Phase 1
  • Phase 2
  • Phase 3

Athenex

Breast cancer

complete

complete

complete

ongoing

Athenex

Luminate®(ALG-1001)

Integrin modulator

  • Preclinical
  • Phase 1
  • Phase 2
  • Phase 3

Allegro

Ophthalmologic disease

complete

complete

complete

uncompleted

Allegro

HM71224(BTK)

Bruton's tyrosine kinase (BTK) inhibitor*Lilly code: LY3337641

  • Preclinical
  • Phase 1
  • Phase 2
  • Phase 3

Lilly

Autoimmune
disease

complete

complete

ongoing

uncompleted

Lilly

poziotinib(pan-HER)

pan-HER inhibitor

Multi-targeted anti-cancer drug

  • Preclinical
  • Phase 1
  • Phase 2
  • Phase 3

Spectrum|Luye

Solid tumors
(breast, lung cancer)

complete

complete

ongoing

uncompleted

Spectrum|Luye

Oratecan(irinotecan + HM30181A)

Oral irinotecan

HM30181A: Oral absorption enhancer

  • Preclinical
  • Phase 1
  • Phase 2
  • Phase 3

Athenex

Colorectal cancer

complete

complete

uncompleted

uncompleted

Athenex

KX2-391(Src/Tubulin)

Src inhibitor and tubulin destabilizer

  • Preclinical
  • Phase 1
  • Phase 2
  • Phase 3

Athenex

Solid tumors

complete

complete

uncompleted

uncompleted

Athenex

HM95573(RAF)

RAF inhibitor

Multi-targeted anti-cancer drug*Genentech code: RG6185

  • Preclinical
  • Phase 1
  • Phase 2
  • Phase 3

Genentech

Solid tumors

complete

Phase 1 ongoing

uncompleted

uncompleted

Genentech

HM43239(FLT3)

FMS-like tyrosine kinase 3 (FLT-3) inhibitor

  • Preclinical
  • Phase 1
  • Phase 2
  • Phase 3

none

Acute Myeloblastic Leukemia (AML)

complete

uncompleted

uncompleted

uncompleted

none

HM81422(FGFR4)

Fibroblast growth factor receptor 4 (FGFR4) inhibitor

  • Preclinical
  • Phase 1
  • Phase 2
  • Phase 3

none

Hepatocellular Carcinoma (HCC)

ongoing

uncompleted

uncompleted

uncompleted

none

LSD1

Lysine-specific histone demethylase 1 (LSD1) inhibitor

  • Preclinical
  • Phase 1
  • Phase 2
  • Phase 3

none

Small Cell Lung Cancer (SCLC)

ongoing

uncompleted

uncompleted

uncompleted

none

BIO
Beijing Hanmi’s New Drug Pipeline
BIO

PD-1/TAA1 Bispecific Antibody

A bispecific antibody for targeted immuno-oncology

  • Preclinical
  • Phase 1
  • Phase 2
  • Phase 3

none

Solid tumor

ongoing

uncompleted

uncompleted

uncompleted

INNOVENT

PD-1/TAA2 Bispecific Antibody

A bispecific antibody for targeted immuno-oncology

  • ongoing
  • Phase 1
  • Phase 2
  • Phase 3

none

Solid tumor

ongoing

uncompleted

uncompleted

uncompleted

none

PD-1/TAA3 Bispecific Antibody

A bispecific antibody for targeted immuno-oncology

  • Preclinical
  • Phase 1
  • Phase 2
  • Phase 3

none

Solid tumor

ongoing

uncompleted

uncompleted

uncompleted

none